Clinical trials: Type 2 Diabetes Mellitus With Diabetic Nephropathy
Diabetes Mellitus, Type 2, Kidney Disease, Chronic
Randomized Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease
Proven therapy for DKD is primarily limited to RAAS blockers and SLGT2i. Weight reduction has the potential to become an additional and much needed treatment option.
- Conditions
- Diabetes Mellitus, Type 2, Kidney Disease, Chronic, Kidney Injury
- Trial name
- OBESE-DKD (NCT04626323)
- Testing
- Roux-en-Y gastric bypass, Best medical treatment
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Hospital Alemão Oswaldo Cruz
Diabetic Nephropathy Type 2 - Uncontrolled, Diabetes Mellitus, Type 2
Mixed Methods Study of Health-Related Social Needs in African American Adults With Chronic Kidney Disease and Type 2 Diabetes Mellitus
The overarching goal of this study is to understand facilitators and barriers to self-care, develop and refine a culturally tailored intervention to improve clinical outcomes, quality of life (QOL), and self-care behaviors in…
- Conditions
- Diabetic Nephropathy Type 2 - Uncontrolled, Diabetes Mellitus, Type 2, Chronic Kidney Diseases
- Trial name
- NCT05692388
- Testing
- Patient and Community Stakeholder Interviews, Cross-sectional Study Participants, Focus Groups and Intervention Mapping
- Where
- United States
- Volunteers
- 330 people
- Sponsor
- Medical College of Wisconsin
Diabetic Nephropathy
Low-dose Colchicine in Patients With Type 2 Diabetes Mellitus and Microalbuminuria
1. The primary objective of this study was： in patients with type 2 diabetes and microalbuminuria who have been receiving stable treatment of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker (ACEI/ARB) for…
- Trial name
- NCT02035891
- Testing
- colchicine 0.5mg/d
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Chongqing Medical University
Essential Hypertension, Type 2 Diabetes
Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy
This study aims to compare the efficacy and safety of Sacubitril/Valsartan versus Valsartan in patients with essential hypertension and type 2 diabetic nephropathy over a 12-week treatment period, including two treatment groups…
- Conditions
- Essential Hypertension, Type 2 Diabetes, Nephropathy
- Trial name
- Hyper-Save (NCT06501651)
- Testing
- Sacubitril/Valsartan, Valsartan
- Where
- China
- Volunteers
- 297 people
- Sponsor
- Sichuan Academy of Medical Sciences
Type 2 Diabetes, Type 2 Diabetes With Renal Manifestations
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
According to the different epidemiological studies in Mexico the prevalence of diabetic nephropathy is 9.1%-40% in diabetic patients, however the complication is subdiagnosed when we see the numbers of uncontrolled diabetics…
- Trial name
- NCT05378282
- Where
- Mexico
- Volunteers
- 40 people
- Sponsor
- Hospital Juarez de Mexico
Diabetic Nephropathy Type 2, Biomarker
Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics.
Diabetic nephropathy (DN) is one of the major microvascular complications associated with diabetic patients, and also the major global cause of chronic kidney disease and end-stage renal disease (ESRD).
- Trial name
- NCT04931537
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Type 2 Diabetes, Diabetic Nephropathy
Role of Sleep Apnea and Sympathetic Activity in Resistant Hypertensive Patients.
Hypertension is highly prevalent in type 2 diabetic patients (NIDDM) with nephropathy, and is the single most important determinant of the rate of renal function loss.
- Conditions
- Type 2 Diabetes, Diabetic Nephropathy, Hypertension, Sleep Apnea
- Trial name
- SAS (NCT01875341)
- Testing
- NCPAP; Nasal continuous positive airway pressure., NCPAP Nasal Continuous Positive Airway Pressure-sub-therapeutic treatment group
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- Ottawa Hospital Research Institute
Diabetic Nephropathies, Diabetes Mellitus, Type II
Environmental Exposure to Lead and Progressive Renal Insufficiency in Type II Diabetic Nephropathy
Background The relationship between long-term heavy lead exposure and chronic interstitial nephropathy is well recognized in the previous literatures.
- Trial name
- NCT00237952
- Testing
- EDTA chelating agents
- Where
- 2 sites in China
- Sponsor
- Chang Gung Memorial Hospital
Diabetic Nephropathies
Intervention Using Vitamin D for Elevated Urinary Albumin Treated With Losartan in Diabetes (IDEAL)
This study is a single center open-label randomized controlled trial designed to evaluate the efficacy of calcitriol plus losartan therapy in subjects with type II diabetes and macroalbuminuria.
- Trial name
- IDEAL (NCT02410005)
- Testing
- Calcitriol, Losartan
- Where
- 3 sites in United States, Qatar
- Volunteers
- 56 people
- Sponsor
- Weill Cornell Medical College in Qatar
Diabetes Mellitus, Diabetic Kidney Disease
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study
SGLT2 inhibitors such as ertugliflozin improve blood pressure and kidney outcomes in people living with diabetes through incompletely understood mechanisms, however, not all patients treated with SGLT2 inhibition have improved…
- Conditions
- Diabetes Mellitus, Diabetic Kidney Disease, Hypertension
- Trial name
- DESIGN (NCT05727579)
- Testing
- Salt-Diet and/or Ertugliflozin, Ertugliflozin 15 mg
- Where
- Netherlands
- Volunteers
- 41 people
- Sponsor
- Amsterdam UMC, location VUmc
Type 2 Diabetic Nephropathy
Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy
The investigators hypothesize that, LPD supplemented with ketoanalogs will reduce urine podocyte loss and lower the angiotensinogen level in the urine.
- Trial name
- NCT01300273
- Testing
- Compound α-Ketoacid Tablet
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Diabetic Nephropathy
Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy
This trial is randomized, placebo-controlled, double blind, double dummy, multi-centre trial. Screening period (4 week) Double blind treatment period (16 weeks)
- Trial name
- NCT01726816
- Testing
- Probucol 250mg/day, Probucol 500mg/day
- Where
- 16 sites in South Korea
- Volunteers
- 126 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Diabetic Nephropathies
Add-on Pentoxifylline to Losartan Versus Increasing Dose of Losartan on NT-PRO BNP in Type 2 Diabetics With Nephropathy
This study was designed to assess the efficacy of adding pentoxifylline to losartan in comparison with increasing dose of losartan in type 2 diabetes patients with nephropathy.
- Trial name
- NCT03006952
- Testing
- Pentoxifylline, Losartan
- Where
- Iran
- Volunteers
- 59 people
- Sponsor
- Tehran University of Medical Sciences
Diabetic Nephropathy
6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria
Current research indicates that TTP488 may be a viable agent for the treatment of diabetic nephropathy. The purpose of this study is to determine the safety and efficacy of a six-month regimen of daily orally-administered TTP488…
- Trial name
- NCT00287183
- Testing
- PF-04494700 (TTP488)
- Where
- 19 sites in Canada
- Volunteers
- 110 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Clinical Utility of a Genomic Predictor Test on the Management of Cardiorenal Complications of Type 2 Diabetes
The goal of this pragmatic trial is to provide Real World Evidence (RWE) on the impact of the result of a polygenic risk prediction test of cardiorenal complications of T2D, so that more patients at high risk of these…
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Diseases, Diabetic Nephropathy Type 2
- Trial name
- GENOCORDIA (NCT06586203)
- Testing
- Polygenic Risk Score
- Where
- 2 sites in Canada
- Volunteers
- 2,714 people
- Sponsor
- Optithera
Diabetic Nephropathy
Study Of Diabetic Nephropathy With Atrasentan
The study objective was to evaluate the effect of atrasentan compared with placebo on time to doubling of serum creatinine (DBSC) or the onset of end-stage renal disease (ESRD) in participants with type 2 diabetes and nephropathy…
- Trial name
- SONAR (NCT01858532)
- Testing
- Atrasentan
- Volunteers
- 5,107 people
- Sponsor
- AbbVie
Chronic Kidney Disease, Diabetic Nephropathy
A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors
The study objective is to investigate the effects of three low doses of atrasentan on urinary albumin/creatinine ratio (UACR) levels in subjects with Type 2 diabetic nephropathy.
- Trial name
- NCT00920764
- Testing
- 0.25 mg Atrasentan QD, 0.75 mg Atrasentan QD, 1.75 mg Atrasentan QD
- Where
- 28 sites in United States, Puerto Rico
- Volunteers
- 92 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Diabetic Kidney Disease, Obesity
Metabolic Phenotypes of Obesity and Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus
1. Comparison between the 4 groups of metabolic phenotypes of obesity as regard the presence and frequency of DKD 2. Relation between DKD , obesity (BMI) and metabolic risk factors in patients with type 2 DM
- Conditions
- Diabetic Kidney Disease, Obesity, Metabolic Syndrome, Diabetes Mellitus, Type 2
- Trial name
- NCT06591104
- Testing
- 24 hour urinary protein
- Volunteers
- 71 people
- Sponsor
- Assiut University
Diabetes Mellitus, Type 2
Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors
Empagliflozin (Jardiance), a highly potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), was approved in Europe in May 2014 for the treatment of type 2 diabetes mellitus (T2DM) to improve glycaemic…
- Trial name
- NCT02864914
- Testing
- Empagliflozin, DPP-4 inhibitors
- Where
- United Kingdom
- Volunteers
- 333,580 people
- Sponsor
- Boehringer Ingelheim
Diabetic Nephropathy Type 2
Study of the Protective Effect of Low-dose Aspirin on Renal Function in Patients With Early Diabetic Nephropathy
This is a multicenter, randomized, placebo-controlled study to evaluate the effectiveness and safety of low-dose aspirin (50 mg/day) in renal and cardiac function protection in people with diabetic nephropathy.
- Trial name
- NCT06068439
- Testing
- Acetylsalicylic Acid
- Volunteers
- 355 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine